The Simple BioTech Podcast - #5 - Alex Zhavoronkov - Artificial Intelligence and Drug/Biomarker Discovery: Why AI Will Play a Massive Role In Pushing BioTech Forward

#5 - Alex Zhavoronkov - Artificial Intelligence and Drug/Biomarker Discovery: Why AI Will Play a Massive Role In Pushing BioTech Forward

05/26/20 • 64 min

Alex Zhavoronkov is a particularly high level human being, originally working in the field of computer science, Alex had a realization that contributing to aging and aging research would be the biggest contribution he could make for humanity. Utilizing his expertise in computer science and artificial intelligence, he began using these skills to enter the world of longevity in a significant way. Artificial intelligence will play a massive role in drug and biomarker discovery going forward and Alex's company, Insilico Medicine is leading the charge in a serious way.
It was an absolute honor to speak with Alex Zhavoronkov as he explained in simple terms
just how exciting Insilico's tech is. How it works, all the different projects they are involved in, and just how much of a financial behemoth Insilico has the potential to be. (Keep an eye out for their IPO in the next few years)
-James Ruhle, SimpleBioTechPodcast.com
Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech
If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Previous Episode

undefined - #4 - Andy Koff - Preventing Quiescent Cells from Turning Senescent - A Unique Approach to Fighting Senescent Cells by Atropos Therapeutics

#4 - Andy Koff - Preventing Quiescent Cells from Turning Senescent - A Unique Approach to Fighting Senescent Cells by Atropos Therapeutics

Andy Koff is the Founder of Atropos Therapeutics. A company with a new approach to tackling senescent cells, one fo the biggest hallmarks of aging.
Atropos Therapeutics uses a bio marker to identify when a cell starts transitioning from a quiescent cell into a senescent cell. Using this bio marker, Atropos aims to be able to prevent the cell from transitioning into a senescent cell, they've dubbed this type of technology a "senosuppressant"
For 25 years or so, starting with his post-graduate work at the Fred Hutchinson Cancer Center with Jim Roberts, and into his faculty position at Memorial Sloan Kettering Cancer Center, Andy has used a multitude of approaches, biochemical, genetic and cellular, to identify the proteins and the mechanisms that control how cells choose between duplicating themselves, known as proliferating, or remaining in a non-proliferating state. This decision is incorrectly made in virtually all cancer cells, thus providing the framework to explain much about how drugs work in oncology.

About five years ago, Andy’s attention shifted to another decision...how cells maintain themselves in the non-proliferating state and what might be the consequences to not being able to do so. His work today has applications in both oncology and in aging and age-related diseases.
-James Ruhle, SimpleBioTechPodcast.com
Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech
If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Next Episode

#6 - Dr. Gregory Bailey - Investing in the Longevity Industry: The Greatest Investment Opportunity in All of Human History

Dr. Gregory Bailey is the CEO of Juvenescence, one of the biggest players in the Longevity industry. Dr. Bailey has a medical degree from the University of Western Ontario and practiced emergency medicine for more than 10 years before entering the world of finance. We talked about all the different things that Juvenescence is working on, as well as some great tips for investing in the capital starved longevity industry. If you want some advice from one of the top investors in the industry, make sure to give this a listen.
Juvenescence has their hands in a lot of different pies... from participating in strategic investments where they know they can add significant value as a company, to launching products like Metabolic Switch, which can instantly turn you into ketosis, due to premier this year.
The longevity industry is starved for cash, but it can be extremely daunting for someone with no formal medical training to make an intelligent investment. Dr. Bailey gives some great advice for getting around this hurdle.
It was an absolute honor to speak with Dr. Gregory Bailey, and the conversation got me more excited than ever to play whatever small part I can in the industry. As his partner Jim Mellon says, this is the greatest investment opportunity in all of human history. Don't sleep on it.
-James Ruhle, SimpleBioTechPodcast.com
Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech
If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

The Simple BioTech Podcast - #5 - Alex Zhavoronkov - Artificial Intelligence and Drug/Biomarker Discovery: Why AI Will Play a Massive Role In Pushing BioTech Forward

Transcript

Speaker 100:00:01.479

The human experience is changing and it's going to happen a lot faster than you think. The world is going to be a vastly different place in the next 10 to 20 years because of what's happening in the biotech industry right now. Welcome to the simple biotech podcast. My name is James rule and I'm your host. The goal of the simple biotech podcast is to interview the researchers, founders, and investors that are working directly in the industry and t